Humacyte, Inc. (HUMA)
0.6852
-0.02
(-2.28%)
USD |
NASDAQ |
Aug 26, 16:00
0.6852
0.00 (0.00%)
After-Hours: 20:00
Humacyte Enterprise Value : 180.92M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 180.92M |
| August 24, 2026 | 170.09M |
| August 21, 2026 | 164.53M |
| August 20, 2026 | 175.42M |
| August 19, 2026 | 190.29M |
| August 18, 2026 | 147.73M |
| August 17, 2026 | 141.87M |
| August 14, 2026 | 154.15M |
| August 13, 2026 | 138.92M |
| August 12, 2026 | 170.87M |
| August 11, 2026 | 183.37M |
| August 10, 2026 | 192.95M |
| August 07, 2026 | 185.65M |
| August 06, 2026 | 183.26M |
| August 05, 2026 | 188.59M |
| August 04, 2026 | 183.98M |
| August 03, 2026 | 177.62M |
| July 31, 2026 | 167.65M |
| July 30, 2026 | 172.70M |
| July 29, 2026 | 159.65M |
| July 28, 2026 | 161.34M |
| July 27, 2026 | 173.40M |
| July 24, 2026 | 159.70M |
| July 23, 2026 | 163.53M |
| July 22, 2026 | 165.20M |
| Date | Value |
|---|---|
| July 21, 2026 | 172.48M |
| July 20, 2026 | 168.42M |
| July 17, 2026 | 170.79M |
| July 16, 2026 | 169.37M |
| July 15, 2026 | 175.48M |
| July 14, 2026 | 182.59M |
| July 13, 2026 | 178.15M |
| July 10, 2026 | 178.84M |
| July 09, 2026 | 180.68M |
| July 08, 2026 | 189.81M |
| July 07, 2026 | 200.29M |
| July 06, 2026 | 200.20M |
| July 02, 2026 | 183.37M |
| July 01, 2026 | 172.98M |
| June 30, 2026 | 202.93M |
| June 29, 2026 | 194.59M |
| June 26, 2026 | 174.54M |
| June 25, 2026 | 154.87M |
| June 24, 2026 | 172.12M |
| June 23, 2026 | 172.72M |
| June 22, 2026 | 203.56M |
| June 18, 2026 | 222.45M |
| June 17, 2026 | 232.33M |
| June 16, 2026 | 245.90M |
| June 15, 2026 | 254.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 282.39B |
| Altimmune, Inc. | 332.01M |
| Protalix Biotherapeutics, Inc. | 161.20M |
| Taysha Gene Therapies, Inc. | 1.618B |
| Agenus, Inc. | 620.93M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.80M |
| Revenue (Quarterly) | 0.406M |
| Total Expenses (Quarterly) | 37.21M |
| EPS Diluted (Quarterly) | -0.1572 |
| Gross Profit Margin (Quarterly) | -423.2% |
| Profit Margin (Quarterly) | -9.06K% |
| Earnings Yield | -71.45% |
| Normalized Earnings Yield | -85.32 |